Molecular therapy. Nucleic acids

Gene replacement therapy using AAV works in retinal models of AIPL1-related early vision loss

Updated

Abstract

Biallelic variations in the AIPL1 gene cause Leber congenital amaurosis subtype 4 (LCA4), an early-onset retinal dystrophy with severe sight impairment.

  • Gene replacement therapy using adeno-associated virus may effectively rescue molecular features associated with LCA4 in human retinal organoid models.
  • Treatment led to the restoration of retinal phosphodiesterase 6 levels and a reduction in elevated cyclic guanosine monophosphate (cGMP) levels.
  • Transcriptomic analysis indicated changes in gene expression linked to the treatment and viral infection.
  • Current evidence suggests that AIPL1 gene therapy could be a promising intervention for LCA4.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free